NCT00354926已完成1 期
Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma
Applied Molecular Evolution22 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2006年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 67
- 试验地点
- 22
- 主要终点
- Adverse Events
研究概览
简要总结
This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.
详细描述
The protein engineering of AME-133v is hypothesized to result in an anti-CD20 therapy with greater potency and efficacy in all patients, but particularly in genetically defined subpopulations that respond poorly to rituximab because they express a low affinity version of the Fc receptor on their immune effector cells. A monoclonal antibody that has increased binding for this receptor should be more effective in stimulating effector cell killing and thus improve response to the antibody.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in the study protocol, subjects have to meet all of the following criteria.
- •Have morphologically confirmed diagnosis of CD-20+ follicular B-cell non-Hodgkin's lymphoma;
- •Have the low affinity form of FcγRIIIa (F/F or F/V at position 158) as determined by FcR genotyping;
- •Have measurable disease. Measurable masses (such as enlarged lymph nodes) must have a clearly defined bi-dimensional diameter of at least 1.5 x 1.5 cm on physical examination or ≤ 1.5 cm in one of the dimensions by CT, MRI, or plain radiograph;
- •Have received prior treatment with chemotherapy given without rituximab; OR, Have not relapsed or progressed within 120 days (inclusive) of the last infusion of rituximab;
- •Be 18 years of age or greater;
- •Have a negative pregnancy test, if relevant. Women of childbearing potential (not postmenopausal for at least one year and not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study. To do this, they must agree to use a medically acceptable contraceptive regimen;
- •Have a performance status of 0 to 2 on the ECOG performance scale;
- •Have adequate hematopoietic, renal, and hepatic function defined as:
- •Absolute neutrophil count greater than 1,500/mm³;
- •Platelet count greater than 75,000/mm³;
- •Hemoglobin at least 8 g/dL;
- •Serum creatinine ≤ 1.5x upper limit of normal;
- •Total bilirubin ≤ 1.5x upper limit of normal;
- •ALT ≤ 1.5 x upper limit of normal;
- •Alkaline phosphatase ≤ 1.5x upper limit of normal.
- •No evidence of hepatitis B or C infection (no detectable HBV DNA or HCV RNA);
- •Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, or other investigational therapy for at least 30 days prior to study enrollment;
- •Have discontinued all high-dose corticosteroid therapy at least 30 days prior to study enrollment (≤ 10 mg/day of Prednisone or equivalent is allowable);
- •Have life expectancy of more than 3 months;
- •Be able to give written informed consent.
排除标准
- •Subjects with any of the following exclusions are not allowed to participate in the study.
- •Allergy to monoclonal antibodies or any of the study drug components;
- •Concurrent malignancy that could complicate interpretation of response evaluation, including any histologic evidence of diffuse B-cell lymphoma. Non-melanoma skin cancer and carcinoma in situ of the cervix are not exclusions;
- •Significant cardiac disease (e.g. NYHA CHF of class III or IV, history of MI within one year prior to study Day 1, unstable angina, uncontrolled hypertension, clinically significant cardiac arrhythmia (CTCAE Grade 2 or higher), or clinically significant baseline ECG or MUGA abnormality.
- •Positive test for serum cardiac troponins (cTnI or cTnT assay; special processing required, and the same assay must be used throughout the study; see Study Reference Manual)
- •Active infection requiring oral or i.v. antibiotics;
- •Administration of blood transfusions or red blood cell growth factors within 10 days preceding enrollment into the protocol;
- •Administration of white cell growth factors within 28 days preceding enrollment into the protocol;
- •Concomitant nonmalignant disease(s) which could interfere with implementation of the protocol, make the study results difficult to interpret, or which represent additional safety risks;
- •History of HIV-associated non-Hodgkin's lymphoma.
结局指标
主要结局
Adverse Events
时间窗: Until the patient is off study (an average of 10 months)
次要结局
未报告次要终点
研究者
研究点 (22)
Loading locations...
相似试验
已完成
1 期
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT01421186MorphoSys AG91
终止
1 期
Study of ET140202 T Cells in Adults With Advanced Hepatocellular CarcinomaLiver NeoplasmHepatocellular CarcinomaMetastatic Liver CancerLiver CancerNCT03998033Eureka Therapeutics Inc.2
招募中
1 期
A Beta-only IL-2 ImmunoTherapY StudyBasal Cell CarcinomaClear Cell Renal Cell CarcinomaMerkel Cell CarcinomaPleural MesotheliomaCutaneous MelanomaSkin CancerMucosal MelanomaOvarian CancerGastric CancerCervical CancerBladder CancerEsophageal CancerNCT05086692Medicenna Therapeutics, Inc.115
已完成
1 期
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03446417Zeno Pharmaceuticals, Inc.34
终止
2 期
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03567616AbbVie8